Skip to search formSkip to main contentSkip to account menu

febuxostat

Known as: 2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid, Febuxostatum, 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic Acid 
An orally available, non-purine inhibitor of xanthine oxidase with uric acid lowering activity. Upon oral administration, febuxostat selectively and… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The authors of a randomised controlled study have reported that secondary outcome measures of all-cause mortality and… 
2016
2016
A novel reverse phase liquid chromatographic technique was developed for the analysis of Febuxostat. Developed method was simple… 
Review
2015
Review
2015
A novel method for the simultaneous estimation of Febuxostat and Diclofenac Potassium in combine dosage form was developed and… 
2014
2014
Article history Gout is a metabolic disorder characterized by elevated uric acid levels in the body, associated with painful… 
2013
2013
A simple, accurate, precise and rapid reversed-phase high performance liquid chromatographic (RP-HPLC) method has been developed… 
2013
2013
Two simple, sensitive, precise and economical UV-spectrophotometric methods have been developed for the determination of… 
2012
2012
The gout space is heating up, but is there sufficient room in the market to accommodate multiple new therapeutics? 
2011
2011
AIM:To study the pharmacokinetics of febuxostat tablets and establish an HPLC method for determining the contents of the… 
2010
2010
Febuxostat more effectively lowers serum uric acid to goal levels than does allopurinol; however, this benefit is offset by a… 
2009
2009
  • 2009
  • Corpus ID: 29750223
(1) For patients with chronic symptomatic hyperuricaemia who fail to respond to a low purine diet, allopurinol is the standard…